MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells

Proceedings of the National Academy of Sciences of the United States of America
Martin S StaegeG W Bornkamm

Abstract

Lymphoblastoid cell lines, generated by immortalization of normal B cells by Epstein-Barr virus (EBV) in vitro, have strong antigen-presenting capacity, are sensitive to EBV-specific cytotoxic T cells, and are highly allostimulatory in mixed lymphocyte culture. By contrast, EBV-positive Burkitt lymphoma (BL) cells are poor antigen presenters, are not recognized by EBV-specific cytotoxic T cells, and are poorly allostimulatory, which raises the question of whether immunological pressure exerted during BL pathogenesis in vivo has selected for a 'nonimmunogenic' tumor phenotype. The present work addresses this question by examining the immunogenicity/antigenicity of cell lines, generated by conversion of a conditionally immortalized lymphoblastoid cell line to permanent growth independent of EBV-latent proteins by introduction of a constitutively active or tetracycline-regulated c-myc gene (A1 and P493-6 cells, respectively). Compared with its parental lymphoblastoid cell line, A1 cells showed many of the features of the nonimmunogenic BL phenotype, namely poor allostimulatory activity, poor antigen-presenting function associated with impaired proteasomal activity, down-regulation of peptide transporter, reduced HLA class I expres...Continue Reading

References

Jan 1, 1979·Immunological Reviews·F M BrodskyW F Bodmer
Jan 1, 1990·Immunogenetics·N M AmariD Meruelo
Jan 1, 1990·Immunogenetics·M D CrewR L Walford
Mar 1, 1986·Human Immunology·S K FoungF C Grumet
Nov 15, 1987·International Journal of Cancer. Journal International Du Cancer·J Avila-CariñoM G Masucci
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A CalenderG M Lenoir
Sep 1, 1982·Tissue Antigens·J ColombaniM Fellous
Jul 4, 1995·International Journal of Cancer. Journal International Du Cancer·M P ImrehM G Masucci
Jan 1, 1993·Advances in Cancer Research·P I Schrier, L T Peltenburg
Sep 17, 1996·Proceedings of the National Academy of Sciences of the United States of America·A PolackB Kempkes
Oct 9, 1996·International Journal of Cancer. Journal International Du Cancer·T FrisanM G Masucci
Jan 1, 1997·Annual Review of Immunology·A B Rickinson, D J Moss
Nov 14, 1997·Proceedings of the National Academy of Sciences of the United States of America·J LevitskayaM G Masucci
Jul 9, 1999·Current Topics in Microbiology and Immunology·U Zimber-StroblG W Bornkamm
Nov 11, 1999·Current Biology : CB·M SchuhmacherF Kohlhuber
Oct 18, 2000·The Journal of Experimental Medicine·A L KovalchukH C Morse
Jan 5, 2001·Nucleic Acids Research·M SchuhmacherD Eick
Aug 24, 2001·International Journal of Cancer. Journal International Du Cancer·A PajicG W Bornkamm

❮ Previous
Next ❯

Citations

Jun 20, 2006·Cancer Immunology, Immunotherapy : CII·Chien-Chung Chang, Soldano Ferrone
Sep 24, 2013·Functional & Integrative Genomics·Bernard Friedenson
Feb 21, 2004·Medical Hypotheses·Hans Helmut NillerJanos Minarovits
Oct 3, 2002·Nature Medicine·Samuel H Speck
Nov 15, 2008·Nature Reviews. Microbiology·David A Thorley-Lawson, Martin J Allday
Mar 22, 2006·The Journal of Experimental Medicine·Dinesh AdhikaryJosef Mautner
May 30, 2006·Journal of Virology·Charles M ChauPaul M Lieberman
Feb 14, 2006·Journal of Virology·Jing YuanElliott Kieff
Oct 19, 2010·Journal of Oncology·Jason M God, Azizul Haque
Nov 21, 2007·Hematology·Gemma L Kelly, Alan B Rickinson
Jul 25, 2009·Blood·Kay KlapprothThomas Wirth
Dec 14, 2011·Clinical & Developmental Immunology·Azim HossainAzizul Haque
Jan 31, 2008·Leukemia & Lymphoma·Shereen AmriaAzizul Haque
Dec 19, 2003·Expert Opinion on Biological Therapy·Graham S Taylor
Aug 26, 2009·Scandinavian Journal of Immunology·C HoennscheidtM S Staege
Jan 11, 2007·International Journal of Cancer. Journal International Du Cancer·Martin SchleeGeorg W Bornkamm
Jan 24, 2009·International Journal of Cancer. Journal International Du Cancer·Georg W Bornkamm
Nov 11, 2008·Seminars in Cancer Biology·Christian Münz, Ann Moormann
Oct 19, 2004·Trends in Microbiology·Hans H NillerJanos Minarovits
Jul 10, 2004·Trends in Molecular Medicine·Wolfgang Hammerschmidt, Bill Sugden
Apr 11, 2008·Experimental Hematology·Martin S StaegeDieter Körholz
Jul 22, 2009·Seminars in Cancer Biology·Bettina GruhneRamakrishna Sompallae
Apr 15, 2017·F1000Research·Brent A Stanfield, Micah A Luftig
Jan 18, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jason M GodAzizul Haque
Oct 24, 2020·Current Clinical Microbiology Reports·Qingxue Li, Jeffrey I Cohen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.